CD38 as immunomodulator in cancer

被引:23
作者
Li, Yanli [1 ]
Yang, Rui [1 ]
Chen, Limo [2 ]
Wu, Sufang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Shanghai, Peoples R China
[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
关键词
biomarker; cancer immunotherapy; CD38; immune checkpoint therapy; immunomodulation; tumor microenvironment; ANTIBODIES TARGETING CD38; MONOCLONAL-ANTIBODIES; BONE-MARROW; ADP-RIBOSE; ANTI-CD38; AUTOANTIBODIES; MULTIPLE-MYELOMA; DENDRITIC CELLS; LUNG-CANCER; EXPRESSION; DARATUMUMAB;
D O I
10.2217/fon-2020-0401
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD38 is a transmembrane glycoprotein that is widely expressed in a variety of human tissues and cells, especially those in the immune system. CD38 protein was previously considered as a cell activation marker, and today monoclonal antibodies targeting CD38 have witnessed great achievements in multiple myeloma and promoted researchers to conduct research on other tumors. In this review, we provide a wide-ranging review of the biology and function of the human molecule outside the field of myeloma. We focus mainly on current research findings to summarize and update the findings gathered from diverse areas of study. Based on these findings, we attempt to extend the role of CD38 in the context of therapy of solid tumors and expand the role of the molecule from a simple marker to an immunomodulator.
引用
收藏
页码:2853 / 2861
页数:9
相关论文
共 50 条
[41]   Evolving roles of CD38 metabolism in solid tumour microenvironment [J].
Gao, Long ;
Du, Xiaohong ;
Li, Jiabin ;
Qin, F. Xiao-Feng .
BRITISH JOURNAL OF CANCER, 2023, 128 (04) :492-504
[42]   Targeting CD38 with daratumumab is lethal to Waldenstrom macroglobulinaemia cells [J].
Paulus, Aneel ;
Manna, Alak ;
Akhtar, Sharoon ;
Paulus, Shumail M. ;
Sharma, Mayank ;
Coignet, Marie V. ;
Jiang, Liuyan ;
Roy, Vivek ;
Witzig, Thomas E. ;
Ansell, Stephen M. ;
Allan, John ;
Furman, Richard ;
Aulakh, Sonikpreet ;
Manochakian, Rami ;
Ailawadhi, Sikander ;
Chanan-Khan, Asher A. ;
Sher, Taimur .
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (02) :196-211
[43]   VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era [J].
Mizuta, Shumpei ;
Kawata, Takahito ;
Kawabata, Hiroshi ;
Yamane, Noriko ;
Mononobe, Saya ;
Komai, Takao ;
Koba, Yusuke ;
Ukyo, Naoya ;
Tamekane, Akira ;
Watanabe, Mitsumasa .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (03) :322-330
[44]   VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months [J].
Courville, Elizabeth L. ;
Yohe, Sophia ;
Shivers, Paula ;
Linden, Michael A. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 153 (02) :221-228
[45]   Targeting CD38 alleviates tumor-induced immunosuppression [J].
Tai, Yu-Tzu ;
Anderson, Kenneth C. .
ONCOTARGET, 2017, 8 (68) :112166-112167
[46]   Roles of CD38 in the Immune Response to Infection [J].
Glaria, Estibaliz ;
Valledor, Annabel F. .
CELLS, 2020, 9 (01)
[47]   Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies [J].
Mustafa, Nurulhuda ;
Azaman, Muhamad Irfan ;
Ng, Giselle G. K. ;
Chng, Wee Joo .
BIOMOLECULES, 2022, 12 (09)
[48]   CD38 and retinoids: a step toward a cure [J].
Malavasi, Fabio .
JOURNAL OF LEUKOCYTE BIOLOGY, 2011, 90 (02) :217-219
[49]   CD38: A Significant Regulator of Macrophage Function [J].
Li, Wentao ;
Li, Yanling ;
Jin, Xi ;
Liao, Qianjin ;
Chen, Zhifang ;
Peng, Honghua ;
Zhou, Yanhong .
FRONTIERS IN ONCOLOGY, 2022, 12
[50]   Evaluation of diagnostic potential of CD38 in rickets [J].
Xia, Yongjie ;
Ye, Xiaoshuo ;
Chen, Wei ;
You, Chao ;
Deng, Chao ;
Zhou, Yibiao .
MOLECULAR AND CELLULAR PROBES, 2024, 73